New drug for treating chest pain approved by Health Canada
A new treatment option has been approved for the symptomatic treatment of patients with stable angina pectoris.
Angina pectoris, in layman's terms, is chest pain associated with coronary heart disease--it occurs when the heart isn't getting enough oxygen, normally due to narrowing or blockage of an artery.
Fortunately for those who are not receptive to first-line antianginal therapies, such as beta-blockers and calcium antagonists, a new drug from Mississauga-based KYE Pharmaceuticals Inc. has been approved by Health Canada.
The drug, CORZYNA provides a dose of ranolazine through extended-release tablets--ranolazine has been available internationally for well over a decade.
The drug is projected to hit the Canadian market by the spring of 2021.
“KYE is extremely pleased to be able to bring this important new class of an anti-anginal medication to Canadian patients and healthcare professionals” Doug Reynolds, president of KYE, said in a news release.
“This is a highlight for KYE and for those Canadian patients suffering from recurrent angina episodes," he continued.
- Canadian pharmaceutical company donating drug that could help fight COVID-19
- Feds working to prevent Canadian drug shortage
- New rapid COVID-19 anti-body test approved by Health Canada
- Health Canada Approves New Form of Treatment for Atopic Dermititis
- McMaster University-led team studying COVID-19 drug treatment
- Male pronounced dead at scene after drowning in Brampton
- PICK A SIDE: When should masks no longer be mandatory in Ontario?
- Special weather statement: Heavy rainfall in Mississauga, Brampton and Hamilton
- Popular breakfast and lunch restaurant opening new location in Mississauga
- 1 in 3 Canadians considering 'workarounds' as Mississauga, Brampton and Hamilton house prices keep rising